{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:53:39Z","timestamp":1794110019240,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ijantimicag.2023.106842","type":"journal-article","created":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T09:47:55Z","timestamp":1683452875000},"page":"106842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-9610","authenticated-orcid":false,"given":"J. Dillon","family":"Frazier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Leigh","family":"Stoudenmire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-7894","authenticated-orcid":false,"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-2520","authenticated-orcid":false,"given":"Geren M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-8652","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Henao-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-643X","authenticated-orcid":false,"given":"Carlos","family":"Franco-Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-0195","authenticated-orcid":false,"given":"Daniel B.","family":"Chastain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106842_bib0001","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0002","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1086\/522186","article-title":"National trends in Staphylococcus aureus infection rates: impact on economic burden and mortality over a 6-year period (1998\u20132003)","volume":"45","author":"Noskin","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0003","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinte.165.15.1756","article-title":"The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database","volume":"165","author":"Noskin","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1056\/NEJMp1212324","article-title":"Post-hospital syndrome \u2013 an acquired, transient condition of generalized risk","volume":"368","author":"Krumholz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jgar.2019.02.007","article-title":"Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections","volume":"17","author":"Rappo","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0007","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dky133","article-title":"Emergency department visits during outpatient parenteral antimicrobial therapy: a retrospective cohort study","volume":"73","author":"Shrestha","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0008","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jhm.2582","article-title":"Perceptions and practices of physicians regarding outpatient parenteral antibiotic therapy in persons who inject drugs","volume":"11","author":"Fanucchi","year":"2016","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0009","doi-asserted-by":"crossref","first-page":"ofab083","DOI":"10.1093\/ofid\/ofab083","article-title":"Low use of outpatient parenteral antimicrobial therapy for drug use-associated infective endocarditis in an urban hospital system","volume":"8","author":"Ceniceros","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0010","doi-asserted-by":"crossref","first-page":"ofaa205","DOI":"10.1093\/ofid\/ofaa205","article-title":"Perspectives of patients on outpatient parenteral antimicrobial therapy: experiences and adherence","volume":"7","author":"Hamad","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0011","doi-asserted-by":"crossref","first-page":"ofy056","DOI":"10.1093\/ofid\/ofy056","article-title":"Outcomes according to discharge location for persons who inject drugs receiving outpatient parenteral antimicrobial therapy","volume":"5","author":"D'Couto","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0012","series-title":"Dalvance (dalbavancin) [package insert]","year":"2021"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0013","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0014","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0015","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \"lineless antibiotics\" for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0016","unstructured":"CenterSquare. This is where Georgia's health care system ranks in the US. 2021."},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0017","unstructured":"University of Wisconsin Population Health Institute. County Health Rankings State Report 2022. Madison, WI: University of Wisconsin Population Health Institute; 2022."},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0018","series-title":"CDC\/ATSDR Social Vulnerability Index 2022","year":"2022"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0019","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"Rybak","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0020","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1592\/phco.29.11.1275","article-title":"Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"29","author":"Rybak","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0021","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0023","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0024","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of Gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0026","doi-asserted-by":"crossref","first-page":"ofac335","DOI":"10.1093\/ofid\/ofac335","article-title":"Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections","volume":"9","author":"Molina","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0027","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0028","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106210","article-title":"Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections","volume":"56","author":"Veve","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2013.02.018","article-title":"Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review","volume":"131","author":"van Boekel","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmacy10010001","article-title":"Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care","volume":"10","author":"Antosz","year":"2021","journal-title":"Pharmacy (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0032","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0034","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0035","article-title":"Health care utilization patterns for patients with a history of substance use requiring OPAT","volume":"8","author":"Ashraf","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0036","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13756-016-0161-0","article-title":"Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study","volume":"6","author":"Grau","year":"2017","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0037","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106069","article-title":"Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review","volume":"56","author":"Thomas","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0039","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0040","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/jac\/dkq355","article-title":"Safe and successful treatment of intravenous drug users with a peripherally inserted central catheter in an outpatient parenteral antibiotic treatment service","volume":"65","author":"Ho","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0041","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1186\/s12879-021-06514-9","article-title":"\"OPTIONS-DC\", a feasible discharge planning conference to expand infection treatment options for people with substance use disorder","volume":"21","author":"Sikka","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.16228","article-title":"Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use-associated infective endocarditis","volume":"3","author":"Kimmel","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0043","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/cid\/ciz654","article-title":"Outpatient parenteral antimicrobial therapy plus buprenorphine for opioid use disorder and severe injection-related infections","volume":"70","author":"Fanucchi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0045","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106842_bib0046","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1093\/cid\/ciaa1354","article-title":"Vancomycin advanced therapeutic drug monitoring: exercise in futility or virtuous endeavor to improve drug efficacy and safety?","volume":"72","author":"Dilworth","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:32Z","timestamp":1760377712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0924857923001218"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106842","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106842"}}